Genetic and environmental factors causing variation in drug response

https://doi.org/10.1016/0027-5107(91)90020-OGet rights and content

Abstract

Large pharmacokinetic variations, ranging in magnitude from 4- to 40-fold, often exist among the members of a given population. These variations create differences in risk of cancer by accelerating metabolic activation of certain environmental carcinogens in some subjects, while retarding such rates in other subjects. To identify specific genetic and environmental causes of large interindividual variations in these rates, several methods have been developed to probe hepatic cytochrome P-450 isozymes responsible for xenobiotic activation. In patients, dynamic interactions occur between genetic and environmental factors causing large individual variations in xenobiotic metabolism. Even the same patient can change dosage requirements with time and condition. Appropriate marker drugs can sensitively indicate pharmacokinetic capacity at any given time in a patient or normal volunteer.

With respect to genetic factors, twin and family studies are the traditional methods used to test pharmacogenetic hypotheses. Representative examples are cited to illustrate how twin and family studies serve this purpose. Monogenic control of large interindividual variations in the activity of approx. 12 P-450 isozymes has been described. Individual metabolic pathways need to be investigated for drugs biotransformed formed by multiple pathways. Since many hepatic P-450 isozymes are extremely sensitive to perturbation by numerous environmental alterations, the critical role of selection criteria is stressed to assure that all subjects of twin and family studies are under as uniform environmental conditions as possible. Otherwise, the operation of genetic factors may be concealed or misinterpreted in studies that do not use gene cloning or protein sequence.

References (69)

  • P.G. Blain et al.

    Family study of antipyrine clearance

    Br. Med. J.

    (1982)
  • E.J. Calabrese

    Ecogenetics: Genetic Variation in Susceptibility to Environmental Agents

  • H.F. Cascorbi et al.

    Genetic and environmental influence on halothane metabolism in twins

    Clin. Pharmacol. Ther.

    (1971)
  • E.F. Ellis et al.

    Pharmacokinetics of theophylline in children with asthma

    Pediatrics

    (1976)
  • L. Endrenyi et al.

    Genetic study of amobarbital elimination based on its kinetics in twins

    Clin. Pharmacol. Ther.

    (1976)
  • D.E. Furst et al.

    Salicylate metabolism in twins: Evidence suggesting a genetic influence and induction of salicylurate formation

    J. Clin. Invest.

    (1977)
  • F. Galton

    The history of twins as a criterion of the relative powers of nature and nurture

    J. Br. Anthropol. Inst.

    (1875)
  • J.J. Grygiel et al.

    Effect of age on patterns of theophylline metabolism

    Clin. Pharmacol. Ther.

    (1980)
  • B.D. Hammock et al.

    Comparison of epoxide hydrolases in the soluble and microsomal fractions of mammalian liver

  • L. Hendeles et al.

    Theophylline: A ‘state of the art’ review

    Pharmacotherapy

    (1983)
  • J.R. Idle et al.

    Polymorphisms of oxidation at carbon centers of drugs and their clinical significance

    Drug Metab. Rev.

    (1979)
  • J.W. Jenne et al.

    Pharmacokinetics of theophylline: Application to adjustment of the clinical dose of aminophylline

    Clin. Pharmacol. Ther.

    (1972)
  • K. Kalow

    Pharmacogenetics: Heredity and the Response to Drugs

  • W. Kalow et al.

    A case of deficiency of N-hydroxylation of amobarbital

    Clin. Pharmacol. Ther.

    (1977)
  • G. Kellermann et al.

    Elimination of antipyrine and benzo[a]-pyrene metabolism in cultured human lymphocytes

    Clin. Pharmacol. Ther.

    (1976)
  • H. Kutt et al.

    Insufficient parahydroxylation as a cause of diphenylhydantoin toxicity

    Neurology

    (1964)
  • B.N. La Du

    Pharmacogenetics: Defective enzymes in relation to reactions to drugs

    Annu. Rev. Med.

    (1972)
  • S.M. Lohmann et al.

    Theophylline metabolism by the rat liver microsomal system

    J. Pharmacol. Exp. Ther.

    (1976)
  • H. Meier

    Experimental Pharmacogenetics: Physiopathology of Hereditary and Pharmacologic Responses

  • Cited by (26)

    • Associations between CYP3A4, CYP3A5 and SCN1A polymorphisms and carbamazepine metabolism in epilepsy: A meta-analysis

      2021, Epilepsy Research
      Citation Excerpt :

      Furthermore, the sensitivity analysis also effectively abrogated the heterogeneity but did not influence the present results (supplemental Fig. S22g). With the development of pharmacogenomics, it has been shown that the variability in individual response to antiepileptic drugs depends not only on non-genetic factors (i.e., age, environment and concomitant medications), but also on genetic factors (Vesell, 1991). In a previous study, it was found that genetic factors accounted for 20–95 percent of the factors of individual differences in drug efficacy (McLeod and Evans, 2001).

    • Individual (Personalized) Vulnerabilities

      2010, Comprehensive Toxicology, Second Edition
    • Human Health and Disease: Interaction Between the Genome and the Environment

      2009, Genomic and Personalized Medicine, Two-Vol Set
    View all citing articles on Scopus
    View full text